Cannabis hyperemesis in a dying patient: symptoms may improve with dose reduction rather than complete cessation | Research

The takeaway

A case of cannabis hyperemesis in a patient with advanced ALS highlights that symptoms may be managed by reducing rather than stopping cannabis, that hot bath behavior may be absent in disabled patients, and that primary symptom management must be considered at end of life.

Palliative care patients using cannabis, their caregivers, and clinicians managing end-of-life cannabis use.

CHS may respond to dose reduction rather than complete cannabis cessation in palliative patients

What the researchers found

In a palliative care patient with advanced ALS, cannabis hyperemesis presented atypically without the classic hot bath behavior (due to physical disability). Symptoms may have improved with dose reduction rather than complete abstinence. Primary symptom management (pain, spasticity, nausea, anxiety) must be balanced against CHS risk.

Why it matters

Most CHS guidance assumes patients can simply stop cannabis. In palliative care, where cannabis may be managing critical symptoms like pain and spasticity in terminal illness, the risk-benefit calculation is different, and dose reduction may be a more realistic option.

The numbers in context

Patient with advanced ALS. CHS diagnosed. Classic hot bath behavior absent due to disability. Dose reduction (rather than complete cessation) may have been sufficient. Primary symptoms managed with cannabis: pain, spasticity, nausea, anxiety.

How the study worked

Single case report with narrative synthesis of CHS literature, focusing on unique considerations for palliative care patients.

What this study cannot tell us

Single case report. The finding that dose reduction may suffice is based on one patient and cannot be generalized. Atypical presentation makes diagnosis challenging. No comparative data on dose reduction vs cessation strategies.

How to read the evidence

Preliminary: single case report with narrative review, though addressing an important clinical gap.

When this study was published

Published in 2019.

The bigger picture

As more end-of-life patients use cannabis for symptom management, CHS will increasingly occur in populations where cessation is not straightforward. Palliative care needs its own framework for CHS management that prioritizes quality of life.

Questions still open

What is the minimum dose reduction needed to resolve CHS symptoms? How common is CHS among palliative care cannabis users? Should palliative cannabis prescribing include proactive CHS screening?

Common questions

Can you treat CHS without stopping cannabis completely?

This case report suggests dose reduction may work in some palliative patients. Standard guidance calls for complete cessation, but for terminally ill patients relying on cannabis for symptom management, the risk-benefit calculation may favor reduction.

Why is CHS different in palliative care?

Disabled patients may not show the classic hot bath behavior. Cannabis may be managing critical symptoms that have no good alternatives. And the usual recommendation of complete cessation may worsen quality of life more than the CHS itself.

Read the original research

Cannabis Hyperemesis Syndrome in Palliative Care: A Case Study and Narrative Review.

Journal of palliative medicine, 22(10), 1227-1231

View on PubMed ↗Publisher’s paper ↗

Citation

Howard, Ileana. (2019). Cannabis Hyperemesis Syndrome in Palliative Care: A Case Study and Narrative Review.. Journal of palliative medicine, 22(10), 1227-1231. https://doi.org/10.1089/jpm.2018.0531